Effect of angiotensin Ⅱ on the proliferation and invasion of CT26 colon cancer cells
YANG Xiao-tian1, SU Zhao-liang2, XU min1
(1. Department of Gastroenterology, Affiliated Hospital of Jiangsu University, Zhenjiang Jiangsu 212001； 2. Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang Jiangsu 212013, China)
Abstract：Objective: To investigate the effect of angiotensin Ⅱ ( Ang Ⅱ) and angiotensin Ⅱ type 1 receptor (AT1R) blocker losartan on the proliferation and invasion of CT26 cells. Methods: The expression of AT1R was detected by immunofluorescence assay. The proliferation in cells treated with various concentration of Ang Ⅱ and losartan was examined by CCK8 assay. The CT26 cells were divided into three groups, control group(routine culture), Ang Ⅱ group (1×10-7moL/L) and losartan+Ang Ⅱ group (first treated with 1×10-6moL/L losartan for 2 h, then treated with 1×10-7moL/L Ang Ⅱ). The capacity of cell invasion was detected by invasion assay. The secretion of TNF α was detected by ELISA assay. The expression of AT1R and TNFα was determined by Western blotting. Results: The immunofluorescence result showed that AT1R was expressed in CT26 cell. Compared with the control group, Ang Ⅱgroup promoted the proliferation and invasion of CT26 cells, upregulated the expression of AT1R and TNFα(all P<0.05). Compared with Ang Ⅱ group, losartan +Ang Ⅱgroup significantly inhibited the proliferation and invasion of CT26 cells, downregulated the expression of AT1R and TNFα (all P<0.05). Conclusion: Ang Ⅱ could promote proliferation and invasion of CT26 cells, while losartan could antagonize the effect induced by Ang Ⅱ.
杨萧天1， 苏兆亮2， 徐岷1. 血管紧张素Ⅱ对结肠癌CT26细胞株增殖及侵袭的影响[J]. 江苏大学学报:医学版, 2018, 28(04): 277-281.
YANG Xiao-tian1, SU Zhao-liang2, XU min1. Effect of angiotensin Ⅱ on the proliferation and invasion of CT26 colon cancer cells. Journal of Jiangsu University(Medicine Edition), 2018, 28(04): 277-281.
［1］Arvelo F, Sojo F, Cotte C. Biology of colorectal cancer\[J\]. Ecancermedicalscience, 2015, 9: 520.［2］RodriguesFerreira S, Abdelkarim M, DillenburgPilla P, et al. Angiotensin Ⅱ facilitates breast cancer cell migration and metastasis\[J\]. PLoS One, 2012, 7(4): e35667.［3］Li SH, Lu HI, Chang AY, et al. Angiotensin Ⅱ type I receptor (AT1R) is an independent prognosticator of esophageal squamous cell carcinoma and promotes cells proliferation via mTOR activation\[J\]. Oncotarget,2016, 7(41):67150-67165.［4］Wolczyk D, ZarembaCzogalla M, HryniewiczJankowska A, et al. TNFα promotes breast cancer cell migration and enhances the concentration of membraneassociated proteases in lipid rafts\[J\]. Cell Oncol(Dordr), 2016, 39(4): 353-363.［5］Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer?\[J\]. Trends Endocrinol Metab, 2005, 16(7):293-299.［6］Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensinIconverting enzyme protect against risk of cancer? \[J\]. Lancet, 1998,352(9123):179-184.［7］Kosugi M, Miyajima A, Kikuchi E, et al. Angiotensin Ⅱ type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer\[J\]. Clin Cancer Res, 2006, 12(9): 2888-2893.［8］Shinto O, Yashiro M, Kawajiri H, et al. Inhibitory effect of a TGFβ receptor typeI inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells \[J\]. Br J Cancer, 2010, 102(5):844-851.［9］Domińska K, LachowiczOchedalska A. The involvement of the reninangiotensin system (RAS) in cancerogenesis\[J\]. Postepy Biochem, 2008, 54(3):294-300.［10］Ha YM, Park EJ, Kang YJ, et al. Valsartan independent of AT1 receptor inhibits tissue factor, TLR2 and 4 expression by regulation of Egr1 through activation of AMPK in diabetic conditions\[J\]. J Cell Mol Med, 2014, 18(10): 2031-2043.［11］Toto R. Angiotensin Ⅱ subtype 1 receptor blockers and renal function\[J\]. Arch Intern Med, 2001, 161(12):1492-1499.［12］Richmond V, Michelini FM, Bueno CA. Small molecules as antiTNF drugs\[J\]. Curr Med Chem, 2015, 22(25):2920-2942.［13］MüllerHermelink N, Braumüller H, Pichler B. TNFR1 signaling and IFNγ signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis\[J\]. Cancer Cell, 2008, 13(6):507-518.［14］姚霜，郑璐，于洋，等. 双重荧光实时定量PCR法检测TNFα mRNA表达水平\[J\]. 江苏大学学报(医学版)，2015，25(6):524-527.［15］Egberts JH, Cloosters V, Noack A, et al. Antitumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis\[J\]. Cancer Res, 2008, 68(5):1443-1450.［16］Radhakrishnan P,Chachadi V,Lin MF, et al.TNFα enhances the motility and invasiveness of prostatic cancer cells by stimulating the expression of selective glycosyl and sulfotransferase genes involved in the synthesis of selectin ligands\[J\]. Biochem Biophys Res Commun, 2011, 409(3): 436-441.［17］Kulbe H， Thompson R, Wilson JL, et al. The inflammatory cytokine tumor necrosis factorα generates an autocrine tumorpromoting network in epithelial ovarian cancer cells\[J\]. Cancer Res, 2007, 67(2): 585-592.［18］Hong H, Jiang L, Lin Y, et al. TNFα promotes lymphangiogenesis and lymphatic metastasis of gallbladder cancer through the ERK1/2/AP1/VEGFD pathway\[J\]. BMC Cancer, 2016, 16: 240.［19］Naritomi H, Fujita T, Ito S, et al. Efficacy and safety of longterm losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: The Japan Hypertension Evaluation with Angiotensin Ⅱ Antagonist Losartan Therapy (JHEALTH) study\[J\]. Hypertens Res, 2008, 31(2):295-304.
2018, Vol. 28 
